Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data

Standard

Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. / Chen, Shaojie; Pürerfellner, Helmut; Meyer, Christian; Acou, Willem-Jan; Schratter, Alexandra; Ling, Zhiyu; Liu, Shaowen; Yin, Yuehui; Martinek, Martin; Kiuchi, Marcio G; Schmidt, Boris; Chun, K R Julian.

In: EUR HEART J, Vol. 41, No. 30, 07.08.2020, p. 2863-2873.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Chen, S, Pürerfellner, H, Meyer, C, Acou, W-J, Schratter, A, Ling, Z, Liu, S, Yin, Y, Martinek, M, Kiuchi, MG, Schmidt, B & Chun, KRJ 2020, 'Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data', EUR HEART J, vol. 41, no. 30, pp. 2863-2873. https://doi.org/10.1093/eurheartj/ehz443

APA

Chen, S., Pürerfellner, H., Meyer, C., Acou, W-J., Schratter, A., Ling, Z., Liu, S., Yin, Y., Martinek, M., Kiuchi, M. G., Schmidt, B., & Chun, K. R. J. (2020). Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. EUR HEART J, 41(30), 2863-2873. https://doi.org/10.1093/eurheartj/ehz443

Vancouver

Bibtex

@article{0818935549f846e38bc323a4d3f0adfa,
title = "Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data",
abstract = "AIMS: The optimal treatment for patients with atrial fibrillation (AF) and heart failure (HF) has been a subject of debate for years. We aimed to evaluate the efficacy and safety of rhythm control strategy in patients with AF complicated with HF regarding hard clinical endpoints.METHODS AND RESULTS: Up-to-date randomized data comparing rhythm control using antiarrhythmic drugs (AADs) vs. rate control (Subset A) or rhythm control using catheter ablation vs. medical therapy (Subset B) in AF and HF patients were pooled. The primary outcomes were all-cause mortality, re-hospitalization, stroke, and thromboembolic events. A total of 11 studies involving 3598 patients were enrolled (Subset A: 2486; Subset B: 1112). As compared with medical rate control, the AADs rhythm control was associated with similar all-cause mortality [odds ratio (OR): 0.96, P = 0.65], significantly higher rate of re-hospitalization (OR: 1.25, P = 0.01), and similar rate of stroke and thromboembolic events (OR: 0.91, P = 0.76,); however, as compared with medical therapy, catheter ablation rhythm control was associated with significantly lower all-cause mortality (OR: 0.51, P = 0.0003), reduced re-hospitalization rate (OR: 0.44, P = 0.003), similar rate of stroke events (OR: 0.59, P = 0.27), greater improvement in left ventricular ejection fraction [weighted mean difference (WMD): 6.8%, P = 0.0004], lower arrhythmia recurrence (29.6% vs. 80.1%, OR: 0.04, P < 0.00001), and greater improvement in quality of life (Minnesota Living with Heart Failure Questionnaire score) (WMD: -9.1, P = 0.007).CONCLUSION: Catheter ablation as rhythm control strategy substantially improves survival rate, reduces re-hospitalization, increases the maintenance rate of sinus rhythm, contributes to preserve cardiac function, and improves quality of life for AF patients complicated with HF.",
keywords = "Anti-Arrhythmia Agents/therapeutic use, Atrial Fibrillation/drug therapy, Catheter Ablation, Heart Failure/drug therapy, Humans, Minnesota, Quality of Life, Stroke Volume, Treatment Outcome, Ventricular Function, Left",
author = "Shaojie Chen and Helmut P{\"u}rerfellner and Christian Meyer and Willem-Jan Acou and Alexandra Schratter and Zhiyu Ling and Shaowen Liu and Yuehui Yin and Martin Martinek and Kiuchi, {Marcio G} and Boris Schmidt and Chun, {K R Julian}",
note = "Published on behalf of the European Society of Cardiology. All rights reserved. {\textcopyright} The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.",
year = "2020",
month = aug,
day = "7",
doi = "10.1093/eurheartj/ehz443",
language = "English",
volume = "41",
pages = "2863--2873",
journal = "EUR HEART J",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "30",

}

RIS

TY - JOUR

T1 - Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data

AU - Chen, Shaojie

AU - Pürerfellner, Helmut

AU - Meyer, Christian

AU - Acou, Willem-Jan

AU - Schratter, Alexandra

AU - Ling, Zhiyu

AU - Liu, Shaowen

AU - Yin, Yuehui

AU - Martinek, Martin

AU - Kiuchi, Marcio G

AU - Schmidt, Boris

AU - Chun, K R Julian

N1 - Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

PY - 2020/8/7

Y1 - 2020/8/7

N2 - AIMS: The optimal treatment for patients with atrial fibrillation (AF) and heart failure (HF) has been a subject of debate for years. We aimed to evaluate the efficacy and safety of rhythm control strategy in patients with AF complicated with HF regarding hard clinical endpoints.METHODS AND RESULTS: Up-to-date randomized data comparing rhythm control using antiarrhythmic drugs (AADs) vs. rate control (Subset A) or rhythm control using catheter ablation vs. medical therapy (Subset B) in AF and HF patients were pooled. The primary outcomes were all-cause mortality, re-hospitalization, stroke, and thromboembolic events. A total of 11 studies involving 3598 patients were enrolled (Subset A: 2486; Subset B: 1112). As compared with medical rate control, the AADs rhythm control was associated with similar all-cause mortality [odds ratio (OR): 0.96, P = 0.65], significantly higher rate of re-hospitalization (OR: 1.25, P = 0.01), and similar rate of stroke and thromboembolic events (OR: 0.91, P = 0.76,); however, as compared with medical therapy, catheter ablation rhythm control was associated with significantly lower all-cause mortality (OR: 0.51, P = 0.0003), reduced re-hospitalization rate (OR: 0.44, P = 0.003), similar rate of stroke events (OR: 0.59, P = 0.27), greater improvement in left ventricular ejection fraction [weighted mean difference (WMD): 6.8%, P = 0.0004], lower arrhythmia recurrence (29.6% vs. 80.1%, OR: 0.04, P < 0.00001), and greater improvement in quality of life (Minnesota Living with Heart Failure Questionnaire score) (WMD: -9.1, P = 0.007).CONCLUSION: Catheter ablation as rhythm control strategy substantially improves survival rate, reduces re-hospitalization, increases the maintenance rate of sinus rhythm, contributes to preserve cardiac function, and improves quality of life for AF patients complicated with HF.

AB - AIMS: The optimal treatment for patients with atrial fibrillation (AF) and heart failure (HF) has been a subject of debate for years. We aimed to evaluate the efficacy and safety of rhythm control strategy in patients with AF complicated with HF regarding hard clinical endpoints.METHODS AND RESULTS: Up-to-date randomized data comparing rhythm control using antiarrhythmic drugs (AADs) vs. rate control (Subset A) or rhythm control using catheter ablation vs. medical therapy (Subset B) in AF and HF patients were pooled. The primary outcomes were all-cause mortality, re-hospitalization, stroke, and thromboembolic events. A total of 11 studies involving 3598 patients were enrolled (Subset A: 2486; Subset B: 1112). As compared with medical rate control, the AADs rhythm control was associated with similar all-cause mortality [odds ratio (OR): 0.96, P = 0.65], significantly higher rate of re-hospitalization (OR: 1.25, P = 0.01), and similar rate of stroke and thromboembolic events (OR: 0.91, P = 0.76,); however, as compared with medical therapy, catheter ablation rhythm control was associated with significantly lower all-cause mortality (OR: 0.51, P = 0.0003), reduced re-hospitalization rate (OR: 0.44, P = 0.003), similar rate of stroke events (OR: 0.59, P = 0.27), greater improvement in left ventricular ejection fraction [weighted mean difference (WMD): 6.8%, P = 0.0004], lower arrhythmia recurrence (29.6% vs. 80.1%, OR: 0.04, P < 0.00001), and greater improvement in quality of life (Minnesota Living with Heart Failure Questionnaire score) (WMD: -9.1, P = 0.007).CONCLUSION: Catheter ablation as rhythm control strategy substantially improves survival rate, reduces re-hospitalization, increases the maintenance rate of sinus rhythm, contributes to preserve cardiac function, and improves quality of life for AF patients complicated with HF.

KW - Anti-Arrhythmia Agents/therapeutic use

KW - Atrial Fibrillation/drug therapy

KW - Catheter Ablation

KW - Heart Failure/drug therapy

KW - Humans

KW - Minnesota

KW - Quality of Life

KW - Stroke Volume

KW - Treatment Outcome

KW - Ventricular Function, Left

U2 - 10.1093/eurheartj/ehz443

DO - 10.1093/eurheartj/ehz443

M3 - SCORING: Journal article

C2 - 31298266

VL - 41

SP - 2863

EP - 2873

JO - EUR HEART J

JF - EUR HEART J

SN - 0195-668X

IS - 30

ER -